EFFECT OF ADDING LULICONAZOLE 1% CREAM TO SYSTEMIC ANTIFUNGAL FOR GLABROUS TINEA

Written informed consent will be taken in Hindi or English, as per the patient’s choice. 2. Diagnosis will be made clinically and confirmed by direct microscopic examination using 10% potassium hydroxide (KOH)mount performed in clinic. 3. Recording of lesions and BSA estimation will be done and clinical photographs will be taken. 4. Patients will be asked to score their pruritus on a Numeric Rating Scale(NRS) from 0(minimum) to 10(maximum). 5. A detailed history of disease onset , duration, course, family history, and previous treatments will be recorded. Systemic antihistaminic drugs will be given to both the groups for pruritus. 7. The included patients shall be randomized to one of the two groups by a computer generated randomization chart. Patients will be given Lulicoanzole 1%cream along with T. Terbinafine 250mg BD and only T. Terbinafine 250mg BD on the basis of Randomisation chart. 8. Clinical assessment at baseline and follow ups will be performed 2 weekly.. 9. This will include recording clinical clearance(as percentage improvement), NRS score and any adverse effects , and a KOH examination from remaining lesions. 10. The end point of treatment in each recruited patient would be a complete cure or failure. 11. Relapse rates will be assessed after 12 weeks of complete cure.12. Decoding of treatment groups would be done on trial completion